Rockefeller Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
Other funds holding AUPH
Rockefeller Capital Management's AUPH Position: Q3 2026 in Review
Rockefeller Capital Management increased its Aurinia Pharmaceuticals (AUPH) stake by 4.5% in Q3 2026, buying an estimated $58.7K and bringing the position to 85,085 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1581.
Rockefeller Capital Management first reported a position in AUPH in Q4 2018 and has held it in 32 quarters since. The position peaked at $2.07M in Q3 2021. 210 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.
- Rockefeller Capital Management held 85,085 shares of Aurinia Pharmaceuticals worth $1.38M as of Q3 2026.
- Rockefeller Capital Management bought 3,681 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $58.7K.
- Aurinia Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #1581 holding.
- Rockefeller Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2018 and has held it in 32 quarters since.
- Rockefeller Capital Management's Aurinia Pharmaceuticals position peaked at $2.07M in Q3 2021.
- 210 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.